Results 51 to 60 of about 8,116 (160)

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care [PDF]

, 2017
Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterised by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations.
Alastair Kent, Albert C M Ong, Brenda de Coninck, Denis Clément, Dorien Peters, Elena Levtchenko, Hendrik Van Poppel, Joost P H Drenth, José Luis Górriz, Klemens Budde, Lorenzo E Derchi, Marianna Eleftheroudi, null null, null null, null null, Olivier Devuyst, Raymond Vanholder, Richard Sandford, Ron T Gansevoort, Tess Harris, Tevfik Ecder, Vicente E Torres, Yves Pirson   +22 more
core   +6 more sources

Defining the polycystin pharmacophore through high‐throughput screening and computational biophysics

British Journal of Pharmacology, EarlyView.
An unbiased high throughput electrophysiology screen identifies potent PKD2L1 channel inhibitors with divergent chemical composition that bind to pore fenestration receptors and stabilise their inactivated state. Abstract Background and Purpose Polycystins (PKD2, PKD2L1) are voltage‐gated and Ca2+‐modulated members of the TRP family of ion channels ...
Eduardo Guadarrama, Carlos G. Vanoye, Paul G. DeCaen   +2 more
wiley   +1 more source

New onset diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease: systematic review protocol [PDF]

, 2015
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder with numerous cysts developing in bilateral kidneys.
Ajabnoor, Barua, de Mattos, Guyatt, Harris, Hernández-Fisac, Kanaan, Kidney Disease: Improving Global Outcomes Transplant Work Group, Mao, McCarthy, Menon, Moher, Oetjen, Perrone, Pietrzak-Nowacka, Pietrzak-Nowacka, Pietrzak-Nowacka, Ruderman, Shamseer, Torra, Torres, Torres, Turkmen   +22 more
core   +1 more source

Lactate and Lactylation in AKI‐to‐CKD: Epigenetic Regulation and Therapeutic Opportunities

Cell Proliferation, EarlyView.
ABSTRACT Lactate is not only a byproduct of glycolysis, but is also considered an energy source, gluconeogenic precursor, signalling molecule and protein modifier during the process of cellular metabolism. The discovery of lactylation reveals the multifaceted functions of lactate in cellular metabolism and opens new avenues for lactate‐related research.
Yi Hou, Dongwei Liu, Zuishuang Guo, Cien Wei, Fengyu Cao, Yue Xu, Qi Feng, Fengxun Liu   +7 more
wiley   +1 more source

A Novel Inhibitor of Methyltransferase SMYD2, AZ505 Protects Against Peritoneal Fibrosis in Mice

Clinical and Experimental Pharmacology and Physiology, Volume 52, Issue 7, July 2025.
AZ505, a highly selective inhibitor of SMYD2, may exhibit an antifibrotic effect in peritoneal fibrosis. ABSTRACT AZ505, a highly selective inhibitor of SMYD2, exhibits an antifibrotic effect in renal fibrosis. Its effect on peritoneal fibrosis remains unexplored.
Taijing Xu, Binbin Cui, Feng Liu, Mengjun Liu, Xiying Hou, Xuan Hong, Hualin Qi   +6 more
wiley   +1 more source

Pkd1 transgenic mice: Adult model of polycystic kidney disease with extrarenal and renal phenotypes [PDF]

, 2010
While high levels of Pkd1 expression are detected in tissues of patients with autosomal dominant polycystic kidney disease (ADPKD), it is unclear whether enhanced expression could be a pathogenetic mechanism for this systemic disorder.
Couillard, Martin, Côté, Olivier, Harris, Peter C., Kurbegovic, Almira, Trudel, Marie, Ward, Christopher J.   +5 more
core   +1 more source

The Vertebrate Breed Ontology: Toward Effective Breed Data Standardization

Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.
ABSTRACT Background Limited universally‐adopted data standards in veterinary medicine hinder data interoperability and therefore integration and comparison; this ultimately impedes the application of existing information‐based tools to support advancement in diagnostics, treatments, and precision medicine.
Kathleen R. Mullen, Imke Tammen, Nicolas A. Matentzoglu, Marius Mather, James P. Balhoff, Elizabeth Esdaile, Gregoire Leroy, Carissa A. Park, Halie M. Rando, Nadia T. Saklou, Tracy L. Webb, Nicole A. Vasilevsky, Christopher J. Mungall, Melissa A. Haendel, Frank W. Nicholas, Sabrina Toro   +15 more
wiley   +1 more source

Caffeine intake by patients with autosomal dominant polycystic kidney disease [PDF]

, 2012
Because caffeine may induce cyst and kidney enlargement in autosomal dominant polycystic kidney disease (ADPKD), we evaluated caffeine intake and renal volume using renal ultrasound in ADPKD patients.
Baxmann, Alessandra Calábria, Heilberg, Ita Pfeferman, Nishiura, José Luiz, Vendramini, Larissa Collis   +3 more
core   +2 more sources

Elucidating the Molecular Landscape of Cystic Kidney Disease: Old Friends, New Friends and Some Surprises

American Journal of Medical Genetics Part A, Volume 197, Issue 6, June 2025.
ABSTRACT Cystic kidney diseases (CyKD) are a diverse group of disorders affecting more than 1 in 1000 individuals. Over 120 genes are implicated, primarily encoding components of the primary cilium, transcription factors, and morphogens. Prognosis varies greatly by molecular diagnosis. Causal variants are not identified in 10%–60% of individuals due to
Deborah Watson, Frank Mentch, Jonathan Billings, Kayleigh Ostberg, Michael E. March, Jennifer M. Kalish, Dong Li, India Cannon, Lisa M. Guay‐Woodford, Erum Hartung, Alanna Strong   +10 more
wiley   +1 more source

Determinantes de dor em pacientes com doença renal policística autossômica dominante [PDF]

, 2013
Pain is the most common symptom reported by ADPKD patients, afflicting approximately 60% of cases and may result from renal hemorrhage, calculi, urinary tract infections, cyst rupture, or due to stretching of the capsule or traction of the renal pedicle.
Eloi, Samara Rodrigues Moreira, Heilberg, Ita Pfeferman, Nishiura, José Luiz   +2 more
core   +3 more sources